trastuzumab-melanotransferrin conjugate (BT2111) / Bioasis - LARVOL DELTA

The activity of a new class of biologics: Trastuzumab conjugates designed to treat brain metastases of HER2+ breast cancers (AACR 2014) - Presentation time: Monday, Apr 07, 2014, 1:00 PM - 5:00 PM; Abstract #2905; "...both BT2111 and trastuzumab completely inhibited the growth of peripheral xenograft tumors (BT474) in athymic mice over the course of the experimental period (5-6 weeks). Conjugation of trastuzumab to MTf does not alter the in vivo anti-tumor activity of trastuzumab, supporting the conclusion that HER2 binding and Fc receptor binding was not significantly affected by conjugation."

Preclinical • Biosimilar • Breast Cancer • Oncology

Transcend, a protein vector for brain delivery, allows trastuzumab to reach the brain at effective concentration after incorporation to form BT2111 (AACR 2014) - Presentation time: Sunday, Apr 06, 2014, 1:00 PM - 5:00 PM; Abstract #642; "When BT2111 and trastruzumab were injected into mice, laser scanning confocal microscopy showed increased distribution of BT2111 in the brain parenchyma when compared to trastuzumab. 10 to 15 times more trastuzumab was delivered in the brain parenchyma when conjugated to MTf."

Preclinical • Biosimilar • Oncology

BT2111: Protection of use/indications patent until 2035 (Bioasis) - Corporate Presentation

Patent